Researcher Spotlight – Carlos Arteaga, MD

Estrogen is the key driver of most breast cancers. Anti-estrogen drugs, such as tamoxifen or aromatase inhibitors, are effective treatments for these cancers. Many estrogen-driven breast cancers, however, will become resistant to the therapy. PFP-funded researcher, Dr. Carlos Arteaga from the University of Texas is conducting studies to look for tumor markers of drug resistance and is devising more effective therapeutic approaches for patients less likely to respond to anti-estrogen therapy.   For additional details, visit